Literature DB >> 22707563

Midkine acts as proangiogenic cytokine in hypoxia-induced angiogenesis.

Ludwig T Weckbach1, Leopold Groesser, Julia Borgolte, Judith-Irina Pagel, Frank Pogoda, Jürgen Schymeinsky, Josef Müller-Höcker, Mehdi Shakibaei, Takashi Muramatsu, Elisabeth Deindl, Barbara Walzog.   

Abstract

The cytokine midkine (MK) promotes tumor growth mainly by inducing angiogenesis. Here, we identified the source of MK in the vascular system under hypoxic conditions and demonstrated the relevance of MK during ischemia of normal tissue. Hypoxia increased MK protein expression in human polymorphonuclear neutrophils (PMN), monocytes, and human umbilical vein endothelial cells (HUVEC) compared with normoxia. Immunoelectron microscopy showed elevated cell surface expression of MK in PMN and monocytes during hypoxia. However, only HUVEC released significant amounts of soluble MK during hypoxia compared with normoxia (301 ± 81 pg/ml vs. 158 ± 45 pg/ml; P < 0.05). Exogenous MK induced neovascularization in a chorioallantoic membrane (CAM) assay compared with negative control as measured by counting the number of branching points per visual field (1,074 ± 54 vs. 211 ± 70; P < 0.05). In a hind limb ischemia model, the angiogenic response was almost completely absent in MK-deficient mice, whereas control animals showed a profound angiogenic response measured as proliferating endothelial cells per visual field (45 ± 30 vs. 169 ± 34; P < 0.01). These unanticipated results identified endothelial cells as the source of soluble MK in the vascular system during hypoxia and defined MK as a pivotal player of angiogenesis during ischemia in nonmalignant tissue.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22707563     DOI: 10.1152/ajpheart.00934.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  36 in total

Review 1.  Structure and function of midkine as the basis of its pharmacological effects.

Authors:  T Muramatsu
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 2.  Midkine in host defence.

Authors:  A Gela; S Jovic; S L Nordin; A Egesten
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

3.  PKCδ/midkine pathway drives hypoxia-induced proliferation and differentiation of human lung epithelial cells.

Authors:  Hanying Zhang; Miyako Okamoto; Evgeniy Panzhinskiy; W Michael Zawada; Mita Das
Journal:  Am J Physiol Cell Physiol       Date:  2014-02-05       Impact factor: 4.249

4.  Lymphangiogenesis: From passive disseminator to dynamic metastatic enabler.

Authors:  Eva Pérez-Guijarro; Glenn Merlino
Journal:  Pigment Cell Melanoma Res       Date:  2017-10-16       Impact factor: 4.693

5.  Protease nexin-1 regulates retinal vascular development.

Authors:  Sonia Selbonne; Deborah Francois; William Raoul; Yacine Boulaftali; Florian Sennlaub; Martine Jandrot-Perrus; Marie-Christine Bouton; Véronique Arocas
Journal:  Cell Mol Life Sci       Date:  2015-06-25       Impact factor: 9.261

Review 6.  Targeting midkine and pleiotrophin signalling pathways in addiction and neurodegenerative disorders: recent progress and perspectives.

Authors:  G Herradón; C Pérez-García
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

7.  Expression of the heparin-binding growth factors Midkine and pleiotrophin during ocular development.

Authors:  Ruda Cui; Peter Lwigale
Journal:  Gene Expr Patterns       Date:  2019-02-27       Impact factor: 1.224

Review 8.  Therapeutic potential of midkine in cardiovascular disease.

Authors:  Kenji Kadomatsu; Péter Bencsik; Anikó Görbe; Csaba Csonka; Kazuma Sakamoto; Satoshi Kishida; Péter Ferdinandy
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 9.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

Review 10.  Lessons from the heart and ischemic limbs: midkine as anti-inflammatory mediator for kidney diseases?

Authors:  Delia Lidia Şalaru; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-12-04       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.